Moderna narrows Q2 net loss…norovirus vaccine falls short in interim analysis
MRNA Moderna Inc
$57.88 +6.22%
차트·분석 보기 → - 1Moderna (MRNA) narrowed its Q2 net loss to $782 million ($1.97 per share), beating market expectations of a $2.03 per-share loss.
- 2Norovirus vaccine candidate mRNA-1403 failed to meet the threshold for early success in a Phase 3 interim analysis, and the stock was down about 5.7% at $54.61 in Friday premarket trading.
- 3Quarterly revenue rose to $145 million, and the company lowered its 2026 cost-of-sales outlook to roughly $1.7 billion while raising its year-end cash outlook to $4.7 billion–$5.2 billion.
This 3-line summary is compiled from the report below.
The Wall Street Journal +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다